KemPharm Analyst Ratings
KemPharm Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/15/2022 | 228.95% | Canaccord Genuity | → $20 | Initiates Coverage On | → Buy |
| 08/17/2022 | 64.47% | HC Wainwright & Co. | $11 → $10 | Maintains | Buy |
| 01/31/2022 | 80.92% | HC Wainwright & Co. | $10 → $11 | Upgrades | Neutral → Buy |
| 04/09/2021 | 64.47% | HC Wainwright & Co. | $12 → $10 | Maintains | Neutral |
| 03/04/2021 | 97.37% | HC Wainwright & Co. | $24 → $12 | Downgrades | Buy → Neutral |
| 01/25/2021 | 360.53% | Roth Capital | → $28 | Initiates Coverage On | → Buy |
| 05/20/2020 | -75.33% | HC Wainwright & Co. | $2.5 → $1.5 | Reiterates | → Buy |
| 11/20/2019 | -58.88% | HC Wainwright & Co. | $3 → $2.5 | Reiterates | → Buy |
| 09/05/2019 | -82.73% | Roth Capital | $4.25 → $1.05 | Downgrades | Buy → Neutral |
| 06/19/2019 | -50.66% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
| 05/23/2018 | 179.61% | Janney Montgomery Scott | → $17 | Initiates Coverage On | → Buy |
| 02/26/2018 | 80.92% | Canaccord Genuity | $7 → $11 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2022 年 9 月 15 日 | 228.95% | Canaccord Genu | → 20 美元 | 启动覆盖范围开启 | → 购买 |
| 08/17/2022 | 64.47% | HC Wainwright & Co. | 11 美元 → 10 美元 | 维护 | 买 |
| 01/31/2022 | 80.92% | HC Wainwright & Co. | 10 美元 → 11 美元 | 升级 | 中性 → 买入 |
| 2021 年 9 月 4 日 | 64.47% | HC Wainwright & Co. | 12 美元 → 10 美元 | 维护 | 中立 |
| 2021 年 4 月 3 日 | 97.37% | HC Wainwright & Co. | 24 美元 → 12 美元 | 降级 | 买入 → 中性 |
| 01/25/2021 | 360.53% | 罗斯资本 | → 28 美元 | 启动覆盖范围开启 | → 购买 |
| 05/20/2020 | -75.33% | HC Wainwright & Co. | 2.5 美元 → 1.5 美元 | 重申 | → 购买 |
| 2019 年 11 月 20 日 | -58.88% | HC Wainwright & Co. | $3 → 2.5 美元 | 重申 | → 购买 |
| 09/05/2019 | -82.73% | 罗斯资本 | 4.25 美元 → 1.05 美元 | 降级 | 买入 → 中性 |
| 06/19/2019 | -50.66% | HC Wainwright & Co. | → 3 美元 | 启动覆盖范围开启 | → 购买 |
| 05/23/2018 | 179.61% | 詹尼蒙哥马利斯科特 | → 17 美元 | 启动覆盖范围开启 | → 购买 |
| 2018 年 2 月 26 日 | 80.92% | Canaccord Genu | 7 美元 → 11 美元 | 维护 | 买 |
KemPharm Questions & Answers
KempHarm 问题与解答
The latest price target for KemPharm (NASDAQ: KMPH) was reported by Canaccord Genuity on September 15, 2022. The analyst firm set a price target for $20.00 expecting KMPH to rise to within 12 months (a possible 228.95% upside). 3 analyst firms have reported ratings in the last year.
Canaccord Genuity于2022年9月15日公布了KempHarm（纳斯达克股票代码：KMPH）的最新目标股价。该分析公司将目标股价定为20.00美元，预计KMPH将在12个月内升至12个月内（可能上涨228.95％）。去年有3家分析公司公布了评级。
The latest analyst rating for KemPharm (NASDAQ: KMPH) was provided by Canaccord Genuity, and KemPharm initiated their buy rating.
Canaccord Genuity对KempHarm（纳斯达克股票代码：KMPH）的最新分析师评级由Canaccord Genuity提供，KempHarm启动了买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KemPharm, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KemPharm was filed on September 15, 2022 so you should expect the next rating to be made available sometime around September 15, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与KempHarm的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。KempHarm的最新评级是在2022年9月15日公布的，因此您应该预计下一个评级将在2023年9月15日左右公布。
While ratings are subjective and will change, the latest KemPharm (KMPH) rating was a initiated with a price target of $0.00 to $20.00. The current price KemPharm (KMPH) is trading at is $6.08, which is within the analyst's predicted range.
虽然评级是主观的，而且会发生变化，但最新的KempHarm（KMPH）评级最初设定为0.00美元至20.00美元。KempHarm（KMPH）目前的交易价格为6.08美元，在分析师的预测区间内。